Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RET E632_L633del |
| Therapy | Pralsetinib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | conflicting |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET E632_L633del | Advanced Solid Tumor | conflicting | Pralsetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gavreto (pralsetinib) inhibited viability in transformed cells expressing RET E632_L633del in culture (PMID: 36166639). | 36166639 |
| RET E632_L633del | Advanced Solid Tumor | conflicting | Pralsetinib | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line expressing RET E632_L633del was less sensitive to Gavreto (pralsetinib) than cells expressing wild-type RET in culture (PMID: 36416226). | 36416226 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36166639) | Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis. | Full reference... |
| (36416226) | A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion. | Full reference... |